Here is a quick snapshot of where each medication stands: Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight loss): Greater average weight loss in trials, dual receptor mechanism, no FDA-approved cardiovascular outcomes indication as of 2026 Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss): Slightly lower average weight loss, single receptor mechanism, FDA-approved for reducing major cardiovascular events in patients with established heart disease Administration: Both are once-weekly injections
S2CID 4984228
It is frequently searched alongside Retatrutide, Semaglutide and other incretin compounds
doi: 10.1016/j.jpsychires.2023.05.041CrossRefGoogle ScholarPubMed McIntyre, RS, Mansur, RB, Rosenblat, JD, Kwan, ATH
Recaps tubes with a conic plastic cap for short-term storage or within laboratory distribution
The majority (91.0%) were Non-Hispanic White